The short answer
Tissue NAD+ levels decline with age across multiple species, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive this decline by increasing CD38 activity. Whether restoring NAD+ reverses age-related changes is a separate question and much less settled.
Key facts
- Decline observed
- Across tissues and species
- Mechanism reported
- Senescent cells increase CD38
- Key paper
- Covarrubias, Nat Metab 2020 (PMID 33199924)
- Review
- Covarrubias, Nat Rev Mol Cell Biol 2021
- Restoration benefit
- Not established in humans
- Human outcome data
- Limited
The observation
NAD+ levels fall with age in multiple tissues and multiple species. This is reasonably well replicated and is the empirical foundation the whole field rests on. It is a description of what happens, and on its own it says nothing about whether the decline causes anything.
The mechanism
Covarrubias and colleagues reported in 2020 that senescent cells promote tissue NAD+ decline by activating CD38. The ectoenzyme that consumes NAD+ outside cells. That is a substantive advance, because it moves the story from a correlation with age to an identified consumer, and it connects NAD+ decline to cellular senescence, which is independently implicated in ageing.
Research material referenced
NAD+ 500mg, third-party HPLC tested
Where the logic gets stretched
From a decline plus a mechanism, it is tempting to conclude that restoring NAD+ will reverse what the decline caused. That does not follow. Falling NAD+ may be a consequence of ageing processes rather than a driver of them, and increasing supply does not necessarily reduce the consumption that caused the fall. The 2021 Nature Reviews Molecular Cell Biology review is careful about this in ways downstream summaries usually are not.
What restoring it has actually shown
Precursor supplementation raises NAD+-related markers in at least some tissues in humans. This part is reasonably supported. What it has not shown is durable change in the clinical outcomes people care about. NADPARK was a phase I trial in Parkinson's disease; Orr's 2024 study in older adults was placebo-controlled and modest in scope. These are early-stage findings.
Why this literature attracts overstatement
A measurable molecule that declines with age, with an identified mechanism and an available intervention, is an unusually clean-looking story. Cleanness invites confidence. The gap between raising a biomarker and changing an outcome is where most of the overstatement lives, and it is the same gap that separates every surrogate endpoint from the thing it stands in for.
What is not claimed here
That NAD+ or its precursors slow ageing, extend life, or affect any condition in any person. The material supplied here is for laboratory research, holds no marketing authorisation, and the trial evidence described concerns precursors administered under clinical supervision.
Frequently asked questions
Does NAD+ really decline with age?
Yes. That observation is reasonably well replicated across tissues and species.
What causes the decline?
Covarrubias 2020 reported that senescent cells drive it by increasing CD38 activity, which consumes NAD+ outside cells.
Does restoring NAD+ reverse ageing effects?
Not established. Precursors raise NAD+-related markers, but durable clinical outcome data does not exist.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCovarrubias AJ et al., Senescent cells promote tissue NAD+ decline via CD38. Nat Metab 2020 (PMID 33199924)pubmed.ncbi.nlm.nih.gov
- PubMedCovarrubias AJ et al., NAD+ metabolism in ageing. Nat Rev Mol Cell Biol 2021 (PMID 33353981)pubmed.ncbi.nlm.nih.gov
- PubMedOrr ME et al., Randomized placebo-controlled trial of nicotinamide riboside in older adults. Geroscience 2024 (PMID 37994989)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More NAD+ articles
- What the Human Trials Actually FoundNADPARK, Orr 2024, Yoshino's Science paper and Yi 2023. Real randomised data - and uniformly on precursors rather than NAD+ itself.
- NAD+, NMN and NR: Three Points on One PathwayNot three competing compounds but three positions in a single conversion sequence. Which has the trial data, and which is hardest to deliver.
- NAD+ Storage: Different Chemistry, Different RisksNot a peptide, so peptide degradation logic does not apply. The bonds at risk are glycosidic and pyrophosphate, and both hydrolyse readily.
- NAD+ Regulatory StatusNo marketing authorisation as a medicine anywhere. Why a precursor's food supplement status proves nothing, and why ageing language is the real hazard here.
- Eighty Daltons Apart, and Metabolically OpposedNADP is NAD plus one phosphate - 743.4 against 663.4 Da. One drives catabolism, the other biosynthesis and antioxidant defence.